Terguride maleate | 37686-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Terguride maleate
• 英文别名: 1-<(5R,8S,10R)-6-methyl-8-ergolinyl>-3,3-diethylurea hydrogen maleate；terguride hydrogen maleate；1-((5R,8S,10R)-6-methyl-8-ergolinyl)-3,3-diethylurea hydrogen maleate；3-[(6aR,9S,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea;(Z)-but-2-enedioic acid
• CAS: 37686-85-4
• 化学式: C₄H₄O₄*C₂₀H₂₈N₄O
• 分子量: 456.542
• InChiKey: SORAZNWVQFKAFD-IBIFCFAISA-N

物化性质

• 熔点：
  190-191°

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 安全说明：
  S36/37/39,S45,S53
• 危险类别码：
  R62

反应信息

• 作为反应物：
  描述：

  乙醇 、 Terguride maleate 在 水 作用下， 反应 5.0h， 以80%的产率得到ethyl N-<(5R,8S,10R)-6-methyl-8-ergolinyl>carbamate
  参考文献：
  名称：

  Cerny, Antonin; Benes, Jan; Vachek, Jaroslav, Collection of Czechoslovak Chemical Communications, 1987, vol. 52, # 5, p. 1331 - 1339

  摘要：

  DOI：

文献信息

• Combination therapies
  申请人：Pfizer Inc

  公开号：US20040209916A1

  公开（公告）日：2004-10-21

  The invention is directed to methods of treating asthma, COPD, allergic rhinitis, and infectious rhinitis by administering a first pharmaceutical agent including one or more compounds selected from the quarternary ammonium compounds of formulae I-V and a second pharmaceutical agent including one or more pharmaceutical agents selected from Adenosine A 2a Receptor Agonists, D2-Dopamine Receptor Agonists, Phosphodiesterase Inhibitors (PDE's), corticosteroids, norepinephrine reuptake inhibitors, 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]-propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one, and pharmaceutically acceptable salts thereof, and non-quarternized antimuscarinic compounds.

  该发明涉及通过给予包括公式I-V的季铵化合物中选取的一个或多个化合物以及包括选自腺苷A2a受体激动剂、D2-多巴胺受体激动剂、磷酸二酯酶抑制剂（PDE's）、皮质类固醇、去甲肾上腺素再摄取抑制剂、4-羟基-7-[2-[2-[3-[2-苯乙氧基]-丙磺酰乙氨基]-乙基]-1,3-苯并噻唑-2(3H)-酮及其药用可接受的盐以及非季铵化的抗胆碱药物的第二药物，来治疗哮喘、COPD、过敏性鼻炎和感染性鼻炎的方法。
• LONG ACTING SUSTAINED-RELEASE FORMULATION CONTAINING DOPAMINE RECEPTOR AGONIST AND THE PREPARATION METHOD THEREOF
  申请人：SHANDONG LUYE PHARMACEUTICAL CO., LTD.

  公开号：EP1797871A1

  公开（公告）日：2007-06-20

  The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight.

  本发明涉及一种用于治疗帕金森病的长效缓释制剂，包括多巴胺受体激动剂和药学上可接受的生物降解聚合物辅料，其中缓释制剂中多巴胺受体激动剂的含量为 5-50%（按重量计），药学上可接受的聚合物辅料的含量为 50-95%（按重量计）。
• COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEROF FOR TREATING OBSTRUCTIVE AIRWAYS
  申请人：Boehringer Ingelheim Pharma GmbH & Co.KG

  公开号：EP1397134A2

  公开（公告）日：2004-03-17
• COMBINATION THERAPIES
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1620083A2

  公开（公告）日：2006-02-01
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.